Emerging drugs for biliary cancer

Expert Opinion on Emerging Drugs

Volumn 12, Issue 4, 2007, Pages 571-589

  Eckel, Florian ^a,b   Schmid, Roland M ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Anti angiogenic therapy; Anti EGF receptor therapy; Biliary tract cancer; Chemotherapy; Cholangiocarcinoma; Gallbladder carcinoma; Receptor tyrosine kinase inhibitors; Targeted therapy

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ADECATUMUMAB; AE 8062A; ANGIOGENESIS INHIBITOR; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BEVACIZUMAB; BIBX 1382; BORTEZOMIB; CA 4P; CAPECITABINE; CARBOHYDRATE DERIVATIVE; CERTOLIZUMAB PEGOL; CGP 59326A; CISPLATIN; DAVANAT; DEXAMPHETAMINE; DOXORUBICIN; E 4G10; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; EXEL 0999; EXEL 2880; EXEL 7647; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; GEFITINIB; GEMCITABINE; HSV 1716; IMATINIB; INTERLEUKIN 6 ANTIBODY; LAPATINIB; MDX 447; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MONOCLONAL ANTIBODY; N [4 (3 BROMOANILINO) 6 QUINAZOLINYL]ACRYLAMIDE; N ACETYLCOLCHINOL PHOSPHATE; NV 196; OSI 7904; OXALIPLATIN; PELITINIB; PEMETREXED; PROTEASOME INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; SORAFENIB; TEMSIROLIMUS; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UFT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR TARGETING AGENT; VATALANIB; WX G 250RIT; XL 119; XL 880;

ADJUVANT THERAPY; ADVANCED CANCER; BILE DUCT CANCER; BILE DUCT CARCINOMA; BLADDER CANCER; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DIARRHEA; DIGESTIVE SYSTEM CANCER; DRUG BLOOD LEVEL; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG TISSUE LEVEL; DRUG TOLERABILITY; GALLBLADDER CARCINOMA; HUMAN; INTRAHEPATIC BILE DUCT; KIDNEY CARCINOMA; LIVER CANCER; LIVER HILUS; LUNG CANCER; LUNG NON SMALL CELL CANCER; MOLECULAR DYNAMICS; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; NONHUMAN; OVARY CANCER; PANCREAS CANCER; REVIEW; RISK FACTOR; SKIN TOXICITY; STOMACH CANCER; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR GROWTH; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; BILIARY TRACT NEOPLASMS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUG INDUSTRY; HUMANS;

EID: 36649008749     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.12.4.571     Document Type: Review

References (81)

1. PATEL T: Cholangiocarcinoma. Nat. Clin. Pract. Gastroenterol. Hepatol. (2006) 3(1):33-42.
2. DE GROEN PC, GORES GJ, LARUSSO NF, GUNDERSON LL, NAGORNEY DM: Biliary tract cancers. N. Engl. J. Med. (1999) 341(18):1368-1378.
3. RAJAGOPALAN V, DAINES WP, GROSSBARD ML, KOZUCH P: Gallbladder and biliary tract carcinoma: a comprehensive update, part 1. Oncology (Huntingt) (2004) 18(7):889-896.
4. LAZCANO-PONCE EC, MIQUEL JF, MUNOZ N et al.: Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J. Clin. (2001) 51(6):349-364.
5. RANDI G, FRANCESCHI S, LA VECCHIA C: Gallbladder cancer worldwide: geographical distribution and risk factors. Int. J. Cancer (2006) 118(7):1591-1602.
6. KHAN SA, DAVIDSON BR, GOLDIN R et al.: Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut (2002) 51 (Suppl. 6):V11-V19.
7. ECKEL F, SCHMID RM: Chemotherapy in advanced biliary tract catcinoma: a pooled analysis of clinical trials. Br. J. Cancer (2007) 96(6):896-902. •• First pooled analysis in BTC defining a standard regimen for palliative chemotherapy.
8. ORTNER ME, CACA K, BERR F et al.: Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology (2003) 125(5):1355-1363. •• First randomised trial of photodynamic therapy in BTC demonstrating a significant survival benefit.
9. ZOEPF T, JAKOBS R, ARNOLD JC, APEL D, RIEMANN JF: Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy. Am. J. Gastroenterol. (2005) 100(11):2426-2430.
10. BERTHIAUME EP, WANDS J: The molecular pathogenesis of cholangiocarcinoma. Semin. Liver Dis. (2004) 24(2):127-137.
11. GLIMELIUS B, HOFFMAN K, SJODEN PO et al.: Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann. Oncol. (1996) 7(6):593-600. •• Randomised trial demonstrating a benefit of chemotherapy concerning quality of life.
12. BURRIS HA III, MOORE MJ, ANDERSEN J et al.: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. (1997) 15(6):2403-2413.
13. ANDRE T, TOURNIGAND C, ROSMORDUC O et al.: Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann. Oncol. (2004) 15(9):1339-1343. •• A positive trial reflecting the reality of patients with advanced BTC due to realistic inclusion criteria.
14. KNOX JJ, HEDLEY D, OZA A et al.: Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a Phase II trial. J. Clin. Oncol. (2005) 23(10):2332-2338.
15. KNOX JJ, HEDLEY D, OZA A et al.: Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the princess margaret hospital experience. Ann. Oncol. (2004) 15(5):770-774.
16. CUNNINGHAM D, CHAU I, STOCKEN D et al.: Phase III randomised comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer. Eur. J. Cancer Suppl. (2005) 3(4):4.
17. HANAHAN D, WEINBERG RA: The hallmarks of cancer. Cell (2000) 100(1):57-70.
18. VOGELSTEIN B, KINZLER KW: Cancer genes and the pathways they control. Nat. Med. (2004) 10(8):789-799.
19. BIRNEY E, STAMATOYANNOPOULOS JA, DUTTA A et al.: Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature (2007) 447(7146):799-816.
20. PATT YZ, HASSAN MM, AGUAYO A et al.: Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer (2004) 101(3):578-586.
21. KIM TW, CHANG HM, KANG HJ et al.: Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer. Ann. Oncol. (2003) 14(7):1115-1120.
22. IKEDA M, OKUSAKA T, UENO H et al.: A Phase II trial of uracil-tegafur (UFT) in patients with advanced biliary tract carcinoma. Jpn J. Clin. Oncol. (2005) 35(8):439-443.
23. FURUSE J, OKUSAKA T, FUNAKOSHI A et al.: Early Phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer. Jpn J. Clin. Oncol. (2006) 36(9):552-556.
24. UENO H, OKUSAKA T, IKEDA M, TAKEZAKO Y, MORIZANE C: Phase II study of S-1 in patients with advanced biliary tract cancer. Br. J. Cancer (2004) 91(10):1769-1774.
25. DOWLATI A, HOPPEL CL, INGALLS ST et al.: Phase I clinical and pharmacokinetic study of rebeccamycin analog NSC 655649 given daily for five consecutive days. J. Clin. Oncol. (2001) 19(8):2309-2318.
26. DOWLATI A, POSEY J, RAMANATHAN RK et al.: Multicenter Phase II and pharmacokinetic study of rebeccamycin analogue (RA) in advanced biliary cancers. Proc. Am. Soc. Clin. Oncol. (2003) 22:(Abstract 1070).
27. ADJEI AA, ERLICHMAN C, SLOAN JA et al.: Phase I and pharmacologic study of sequences of gemcitabine and the multitatgeted antifolate agent in patients with advanced solid tumors. J. Clin. Oncol. (2000) 18(8):1748-1757.
28. MCWILLIAMS RR, FOSTER NR, QUEVEDO FJ et al.: NCCTG Phase I/II trial (N9943) of gemcitabine and pemetrexed in patients with biliary tract or gallbladder carcinoma: Phase II results. Proc. Am. Soc. Clin. Oncol. (2007) 25(18S):(Abstract 4578).
29. PHILIP PA, MAHONEY MR, ALLMER C et al.: Phase II study of erlotinib in patients with advanced biliary cancer. J. Clin. Oncol. (2006) 24(19):3069-3074.
30. OGOY, NIO Y, YANO S et al.: Immunohistochemical expression of HER-1 and HER-2 in extrahepatic biliary carcinoma. Anticancer Res. (2006) 26(1B):763-770.
31. THOMAS M, TARCO E, TRIVEDI S et al.: Amplification of HER-2/neu (erbB2) gene expression in gallbladder (GBC) and in bile duct cancer (BDC) (biliary tract cancer, BTC). Proc. Am. Soc. Clin. Oncol. (2006) 24(18S):(Abstract 4011).
32. JOHNSON BE, JANNE PA: Epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Cancer Res. (2005) 65(17):7525-7529.
33. AGLIETTA M, PIGNOCHINO Y, CAVALLONI G et al.: Somatic mutations of EGFR signal transducers and expression of tumor suppressor PTEN in biliary tract carcinoma. Proc. Am. Soc. Clin. Oncol. (2007) 25(18S): (Abstract 4582).
34. YOON JH, GWAK GY, LEE HS et al.: Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells. J. Hepatol. (2004) 41(5):808-814.
35. ARIYAMA H, QIN B, BABA E et al.: Gefitinib, a selective EGFR tyrosine kinase inhibitor, induces apoptosis through activation of Bax in human gallbladder adenocarcinoma cells. J. Cell Biochem. (2006) 97(4):724-734.
36. MIYATA H, SASAKI T, KUWAHARA K, SERIKAWA M, CHAYAMA K: The effects of ZD1839 (Iressa), a highly selective EGFR tyrosine kinase inhibitor, as a radiosensitiser in bile duct carcinoma cell lines. Int. J. Oncol. (2006) 28(4):915-921.
37. WIEDMANN M, FEISTHAMMEL J, BLUTHNER T et al.: Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib. Anticancer Drugs (2006) 17(7):783-795.
38. RAMANATHAN RK, BELANI CP, SINGH DA et al.: Phase II study of lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase 1 and 2 (Her2/Neu) in patients (pts) with advanced biliary tree cancer (BTC) or hepatocellular cancer (HCC). A California consortium (CCC-P) trial. Proc. Am. Soc. Clin. Oncol. (2006) 24:(Abstract 4010).
39. SAFRAN H, IANNITTI D, MINER T et al.: GW572016, gemcitabine and GW572016, gemcitabine, oxaliplatin, a two-stage, Phase I study for advanced pancreaticobiliary cancer. Proc. Am. Soc. Clin. Oncol. (2006) 24(18S):(Abstract 4002).
40. SIEMANN DW, BIBBY MC, DARK GG et al.: Differentiation and definition of vascular-targeted therapies. Clin. Cancer Res. (2005) 11(2 Part 1):416-420.
41. HIDA Y, MORITA T, FUJITA M et al.: Vascular endothelial growth factor expression is an independent negative predictor in extrahepatic biliary tract carcinomas. Anticancer Res. (1999) 19(3B):2257-2260.
42. OKITA S, KONDOH S, SHIRAISHI K et al.: Expression of vascular endothelial growth factor correlates with tumor progression in gallbladder cancer. Int. J. Oncol. (1998) 12(5):1013-1018.
43. CLARK JW, MEYERHARDT JA, SAHANI DV et al.: Phase II study of gemcitabine, oxaliplatin in combination with bevacizumab (GEMOX-B) in patients with unresectable or metastatic biliary tract and gallbladder cancers. Proc. Am. Soc. Clin. Oncol. (2007) 25(18S):(Abstract 4625).
44. KINDLER HL, NIEDZWIECKI D, HOLLIS D et al.: A double-blind, placebo-controlled, randomized Phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): a preliminary analysis of cancer and leukemia group B (CALGB). Proc. Am. Soc. Clin. Oncol. (2007) 25(18S): (Abstract 4508).
45. LANGNER C, LEMMERER M, KORNPRAT P: Analysis of KIT (CD117) expression in gallbladder carcinomas by tissue microarray. Eur. J. Surg. Oncol. (2004) 30(8):847-850.
46. KAMENZ T, CACA K, BLUTHNER T et al.: Expression of c-kit receptor in human cholangiocarcinoma and in vivo treatment with imatinib mesilate in chimeric mice. World J. Gastroenterol. (2006) 12(10):1583-1590.
47. SAETTA AA, PAPANASTASIOU P, MICHALOPOULOS NV et al.: Mutational analysis of BRAF in gallbladder carcinomas in association with K-ras and p53 mutations and microsatellite instability. Virchows Arch. (2004) 445(2):179-182.
48. TANNAPFEL A, SOMMERER F, BENICKE M et al.: Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut (2003) 52(5):706-712.
49. TIAN Y, DING RY, ZHI YH, GUO RX, WU SD: Analysis of p53 and vascular endothelial growth factor expression in human gallbladder carcinoma for the determination of tumor vascularity. World J. Gastroenterol. (2006) 12(3):415-419.
50. HUETHER A, HOPFNER M, BARADARI V, SCHUPPAN D, SCHERUBL H: Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma. Biochem. Pharmacol. (2007) 73(9):1308-1317.
51. EL-AB, RANKIN C, LENZ HJ et al.: SWOG 0514: A Phase II study of sorafenib (BAY 43-9006) as single agent in patients (pts) with unresectable or metastatic gallbladder cancer or cholangiocarcinomas. Proc. Am. Soc. Clin. Oncol. (2007) 25(18S):(Abstract 4639).
52. SAWADA T, OKADA T, KUBOTA K: Rapamycin inhibits the growth of cholangiocarcinoma cells in vitro. Proc. Am. Soc. Clin. Oncol. (2007) 25(18S):(Abstract 15153).
53. JIMENO A, RUBIO-VIQUEIRA B, AMADOR ML et al.: Dual mitogen-activated protein kinase and epidermal growth factor receptor inhibition in biliary and pancreatic cancer. Mol. Cancer Ther. (2007) 6(3):1079-1088.
54. TANIMURA Y, KOKURYO T, TSUNODA N et al.: TNF-α promotes invasiveness of cholangiocarcinoma cells via its receptor, TNFR2. Cancer Lett. (2005) 219(2):205-213.
55. SHI JS, ZHOU LS, HAN Y et al.: Expression of tumor necrosis factor and its receptor in gallstone and gallbladdet carcinoma tissue. Hepatobiliary Pancreat. Dis. Int. (2004) 3(3):448-452.
56. SANDS BE, ANDERSON FH, BERNSTEIN CN et al.: Infliximab maintenance therapy for fistulizing Crohn's disease. N. Engl. J. Med. (2004) 350(9):876-885.
57. TAKEDA K, STAGG J, YAGITA H, OKUMURA K, SMYTH MJ: Targeting death-inducing receptors in cancer therapy. Oncogene (2007) 26(25):3745-3757.
58. TANIAI M, GRAMBIHLER A, HIGUCHI H et al.: Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res. (2004) 64(10):3517-3524.
59. KOBAYASHI S, WERNEBURG NW, BRONK SF, KAUFMANN SH, GORES GJ: Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology (2005) 128(7):2054-2065.
60. PANICHAKUL T, INTACHOTE P, WONGKAJORSILP A, SRIPA B, SIRISINHA S: Triptolide sensitizes resistant cholangiocarcinoma cells to TRAIL-induced apoptosis. Anticancer Res. (2006) 26(1A):259-265.
61. USTUNDAG Y, BRONK SF, GORES GJ: Proteasome inhibition-induces endoplasmic reticulum dysfunction and cell death of human cholangiocarcinoma cells. World J. Gastroenterol. (2007) 13(6):851-857.
62. ALBERTS SR, FOSTER NR, MORTON RF et al.: PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a north central cancer treatment group (NCCTG) randomized Phase II study. Ann. Oncol. (2005) 16(10):1654-1661.
63. LAVON I, PIKARSKY E, GUTKOVICH E et al.: NF-κB protects the liver against genotoxic stress and functions independently of p53. Cancer Res. (2003) 63(1):25-30.
64. SADIKOT RT, ZENG H, JOO M et al.: Targeted immunomodulation of the NF-κB pathway in airway epithelium impacts host defense against Pseudomonas aeruginosa. J. Immunol. (2006) 176(8):4923-4930.
65. ALGUL H, TANDO Y, SCHNEIDER G et al.: Acute experimental pancreatitis and NF-κB/Rel activation. Pancreatology (2002) 2(6):503-509.
66. WEHBE H, HENSON R, MENG F, MIZE-BERGE J, PATEL T: Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression. Cancer Res. (2006) 66(21):10517- 10524.
67. METZ S, WIESINGER M, VOGT M et al.: Characterization of the interleukin (IL)-6 inhibitor IL-6-RFP: fused receptor domains act as high affinity cytokine-binding proteins. J. Biol. Chem. (2007) 282(2):1238-1248.
68. SCHELLER J, OHNESORGE N, ROSE-JOHN S: Interleukin-6 trans-signalling in chronic inflammation and cancer. Scand. J. Immunol. (2006) 63(5):321-329.
69. LEE S, KIM WH, JUNG HY, YANG MH, KANG GH: Aberrant CpG island methylation of multiple genes in intrahepatic cholangiocarcinoma. Am. J. Pathol. (2002) 161(3):1015-1022.
70. ISOMOTO H, MOTT JL, KOBAYASHI S et al.: Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing. Gastroenterology (2007) 132(1):384-396.
71. VARGA M, OBRIST P, SCHNEEBERGER S et al.: Overexpression of epithelial cell adhesion molecule antigen in gallbladder carcinoma is an independent marker for poor survival. Clin. Cancer Res. (2004) 10(9):3131-3136.
72. PRANG N, PREITHNER S, BRISCHWEIN K et al.: Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancet cell lines. Br. J. Cancer (2005) 92(2):342-349.
73. LEELAWAT K, LEELAWAT S, RATANACHU-EK T et al.: Circulating hTERT mRNA as a tumor marker in cholangiocarcinoma patients. World J. Gastroenterol. (2006) 12(26):4195-4198.
74. LUZAR B, POLJAK M, COR A, KLOPCIC U, FERLAN-MAROLT V: Expression of human telomerase catalytic protein in gallbladder carcinogenesis. J. Clin. Pathol. (2005) 58(8):820-825.
75. QIU J, LIL GW SUI YF et al.: Truncated TERT mRNA transfected dendritic cells evoke TERT specific antitumor response in vivo. Hepatogastroenterology (2007) 54(75):681-687.
76. ZHI YH, LIU RS, SONG MM et al.: Cyclooxygenase-2 promotes angiogenesis by increasing vascular endothelial growth factor and predicts prognosis in gallbladder carcinoma. World J. Gastroenterol. (2005) 11(24):3724-3728.
77. WU T: Cyclooxygenase-2 and prostaglandin signaling in cholangiocarcinoma. Biochim. Biophys. Acta (2005) 1755(2):135-150.
78. SIRICA AE: Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Hepatology (2005) 41(1):5-15. • Overview of molecular targeting strategies in cholangiocarcinoma with respect of chemoprevention.
79. AJANI JA: Standatd of care for gastric cancer based on meta-analysis? Treading on thin ice or it is vety nice! J. Clin. Oncol. (2006) 24(34):5473-5474; author reply 5474-5476.
80. http://www.pharmaprojects.com Pharmaprojects © Informa UK Ltd (2007).
81. http://www.clinicaltrials.gov Clinical Trials website.